

## 5. REFERENCES

- [1] Pan American Health Organization, “The burden of drug use disorders in the Region of the Americas, 2000-2019,” *Noncommunicable Diseases and Mental Health Data Portal. Pan American Health Organization*, 2021. <https://www.paho.org/en/enlace/burden-drug-use-disorders> (accessed Jan. 02, 2023).
- [2] Institute for Health Metrics and Evaluation, “Global Burden of Disease data visualization,” *Institute for Health Metrics and Evaluation*, 2019. <https://www.healthdata.org/> (accessed Jan. 27, 2023).
- [3] L. J. Paulozzi, D. S. Budnitz, and Y. Xi, “Increasing deaths from opioid analgesics in the United States.,” *Pharmacoepidemiol Drug Saf*, vol. 15, no. 9, pp. 618–627, Nov. 2006, doi: 10.1002/pds.1276.
- [4] “Overdose Death Rates | National Institute on Drug Abuse (NIDA).” <https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates> (accessed Jan. 02, 2023).
- [5] C. L. Mattson, L. J. Tanz, K. Quinn, M. Kariisa, P. Patel, and N. L. Davis, “Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths — United States, 2013–2019,” *MMWR Morb Mortal Wkly Rep*, vol. 70, no. 6, pp. 202–207, Feb. 2022, doi: 10.15585/MMWR.MM7006A4.

- [6] T. Vos *et al.*, “Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019,” *The Lancet*, vol. 396, no. 10258, pp. 1204–1222, Oct. 2020, doi: 10.1016/S0140-6736(20)30925-9.
- [7] J. E. Goldstick, A. Zeoli, C. Mair, and R. M. Cunningham, “Us firearm-related mortality: National, state, and population trends, 1999–2017,” *Health Aff*, vol. 38, no. 10, pp. 1646–1652, Oct. 2019, doi: 10.1377/HLTHAFF.2019.00258/ASSET/IMAGES/LARGE/FIGUREEX6.JPEG.
- [8] Johns Hopkins Center for Gun Violence Solutions, “A Year in Review,” 2022. [Online]. Available: <https://publichealth.jhu.edu/gun-violence-solutions>.
- [9] M. Luy, P. di Giulio, V. di Lego, P. Lazarevič, and M. Sauerberg, “Life Expectancy: Frequently Used, but Hardly Understood,” *Gerontology*, vol. 66, no. 1, pp. 95–104, Jan. 2020, doi: 10.1159/000500955.
- [10] E. Arias, B. Tejada-Vera, F. Ahmad, and K. D. Kochanek, “Vital Statistics Rapid Release Provisional Life Expectancy Estimates for 2020,” 2020. [Online]. Available: <https://www.cdc.gov/nchs/products/index.htm>.
- [11] “Life Expectancy in the U.S. Dropped for the Second Year in a Row in 2021.” [https://www.cdc.gov/nchs/pressroom/nchs\\_press\\_releases/2022/20220831.htm](https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220831.htm) (accessed Jan. 02, 2023).

- [12] J. Y. Ho and A. S. Hendi, “Recent trends in life expectancy across high income countries: Retrospective observational study,” *BMJ (Online)*, vol. 362, 2018, doi: 10.1136/bmj.k2562.
- [13] S. Preston, P. Heuveline, and M. Guillot, *Demography: Measuring and Modeling Population Processes*. Wiley-Blackwell, 2001. [Online]. Available: <http://www.blackwe>
- [14] H. Hedegaard, A. M. Miniño, and M. Warner, “Drug Overdose Deaths in the United States, 1999-2019.,” *NCHS Data Brief*, no. 394, pp. 1–8, Nov. 2020, [Online]. Available: <https://pubmed.ncbi.nlm.nih.gov/33395384/>
- [15] Statista, “Number of firearm deaths in the U.S. 2019.” <https://www.statista.com/statistics/258913/number-of-firearm-deaths-in-the-united-states/> (accessed Jan. 05, 2023).
- [16] J. Y. Ho, “The Contemporary American Drug Overdose Epidemic in International Perspective,” *Popul Dev Rev*, vol. 45, no. 1, pp. 7–40, Mar. 2019, doi: 10.1111/PADR.12228.
- [17] D. Nand *et al.*, “Global mortality from firearms, 1990-2016,” *JAMA - Journal of the American Medical Association*, vol. 320, no. 8, pp. 792–814, Aug. 2018, doi: 10.1001/jama.2018.10060.
- [18] A. Lawrence, A. Kaul, and M. Seaver, “Chronic Pain,” *The 5-Minute Clinical Consult Standard 2016: Twenty Fourth Edition*, Nov. 2022, doi: 10.1542/9781581109689-part01-ch40.

- [19] R. Lappin, “CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016,” *MMWR. Recommendations and Reports*, vol. 65, no. 4, pp. 150–151, Apr. 2022, doi: 10.15585/MMWR.RR6501E1ER.
- [20] D. Dowell, K. R. Ragan, C. M. Jones, G. T. Baldwin, and R. Chou, “CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022,” *MMWR. Recommendations and Reports*, vol. 71, no. 3, pp. 1–95, Nov. 2022, doi: 10.15585/MMWR.RR7103A1.
- [21] S. Darke and D. Zador, “Fatal heroin ‘overdose’: a review,” *Addiction*, vol. 91, no. 12, pp. 1765–1772, Dec. 1996, doi: 10.1046/J.1360-0443.1996.911217652.X.
- [22] I. van Beek, J. Kimber, A. Dakin, and S. Gilmour, “The Sydney Medically Supervised Injecting Centre: reducing harm associated with heroin overdose,” *Crit Public Health*, vol. 14, no. 4, pp. 391–406, 2004, doi: 10.1080/09581590400027528.
- [23] K. Willis, *Evaluation of the Impact of Drug Summit Initiatives in Two NSW Regions*. Australian Institute of Criminology for the NSW Cabinet Office, 2002.
- [24] National Committee on Violence, *Violence: Directions for Australia*. Canberra: Australian Institute of Criminology, 1990.